AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Articles
July 11, 2012

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline
A multicenter study

P. Murali Doraiswamy, MD, Reisa A. Sperling, MD, R. Edward Coleman, MD, Keith A. Johnson, MD, Eric M. Reiman, MD, Mat D. Davis, MS, Michael Grundman, MD, MPH, … Show All … , Marwan N. Sabbagh, MD, Carl H. Sadowsky, MD, Adam S. Fleisher, MD, MAS, Alan Carpenter, PhD, Christopher M. Clark, MD, Abhinay D. Joshi, MS, Mark A. Mintun, MD, Daniel M. Skovronsky, MD, PhD, and Michael J. Pontecorvo, PhD For the AV45-A11 Study GroupAuthors Info & Affiliations
October 16, 2012 issue
79 (16) 1636-1644
https://doi.org/10.1212/WNL.0b013e3182661f74
Letters to the Editor
Track CitationsAdd to favorites
Get Access

Abstract

Objectives:

Florbetapir F 18 PET can image amyloid-β (Aβ) aggregates in the brains of living subjects. We prospectively evaluated the prognostic utility of detecting Aβ pathology using florbetapir PET in subjects at risk for progressive cognitive decline.

Methods:

A total of 151 subjects who previously participated in a multicenter florbetapir PET imaging study were recruited for longitudinal assessment. Subjects included 51 with recently diagnosed mild cognitive impairment (MCI), 69 cognitively normal controls (CN), and 31 with clinically diagnosed Alzheimer disease dementia (AD). PET images were visually scored as positive (Aβ+) or negative (Aβ−) for pathologic levels of β-amyloid aggregation, blind to diagnostic classification. Cerebral to cerebellar standardized uptake value ratios (SUVr) were determined from the baseline PET images. Subjects were followed for 18 months to evaluate changes in cognition and diagnostic status. Analysis of covariance and correlation analyses were conducted to evaluate the association between baseline PET amyloid status and subsequent cognitive decline.

Results:

In both MCI and CN, baseline Aβ+ scans were associated with greater clinical worsening on the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog (p < 0.01) and Clinical Dementia Rating–sum of boxes (CDR-SB) (p < 0.02). In MCI Aβ+ scans were also associated with greater decline in memory, Digit Symbol Substitution (DSS), and Mini-Mental State Examination (MMSE) (p < 0.05). In MCI, higher baseline SUVr similarly correlated with greater subsequent decline on the ADAS-Cog (p < 0.01), CDR-SB (p < 0.03), a memory measure, DSS, and MMSE (p < 0.05). Aβ+ MCI tended to convert to AD dementia at a higher rate than Aβ− subjects (p < 0.10).

Conclusions:

Florbetapir PET may help identify individuals at increased risk for progressive cognitive decline.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

Supplementary Material

File (appendix_e-1.docx)
File (coinvestigators.docx)
File (figure_e-1.docx)
File (table_e-1.docx)
File (table_e-2.docx)
File (znl04012001628.pdf)

REFERENCES

1.
Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011;76:280–286.
Crossref
PubMed
Google Scholar
2.
Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270–279.
Crossref
PubMed
Google Scholar
3.
Weiner MW, Aisen PS, Jack CR, et al. Alzheimer's Disease Neuroimaging Initiative: progress report and future plans. Alzheimer Dement 2010;6:202–211.
Crossref
PubMed
Google Scholar
4.
The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1–S2.
PubMed
Google Scholar
5.
Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:6820–6285.
Crossref
PubMed
Google Scholar
6.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound B. Ann Neurol 2004;55:306–319.
Crossref
PubMed
Google Scholar
7.
Nordberg A, Rinne JO, Kadir A, Långström B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010;6:78–87.
Crossref
PubMed
Google Scholar
8.
Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469–1475.
Crossref
PubMed
Google Scholar
9.
Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PiB PET study. Neurology 2009;73:754–760.
Crossref
PubMed
Google Scholar
10.
Jack CR, Wiste HJ, Vemuri P, et al., Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336–3348.
Crossref
PubMed
Google Scholar
11.
Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011;76:1085–1090.
Crossref
PubMed
Google Scholar
12.
Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181–192.
Crossref
PubMed
Google Scholar
13.
Villemagne VL, Pike KE, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008;46:1688–1697.
Crossref
PubMed
Google Scholar
14.
Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557–568.
Crossref
PubMed
Google Scholar
15.
Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-β peptide deposition identified with Pittsburgh compound B. Arch Neurol 2009;66:1476–1481.
Crossref
PubMed
Google Scholar
16.
Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-β measured by [11C]PiB. Neurology 2010;74:807–815.
Crossref
PubMed
Google Scholar
17.
Pontecorvo M, Mintun M. PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimers Res Ther 2011;3:11.
Crossref
PubMed
Google Scholar
18.
Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009;50:1887–194.
Crossref
PubMed
Google Scholar
19.
Clark CM, Schneider JA, Bedell BJ, et al., AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275–283.
Crossref
PubMed
Google Scholar
20.
Barthel H, Gertz HJ, Dresel S, et al., for the Florbetaben Study Group. Cerebral amyloid-β PET with florbetaben (18)F in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424–435.
Crossref
PubMed
Google Scholar
21.
Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129–135.
Crossref
PubMed
Google Scholar
22.
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group on Alzheimer's disease. Neurology 1984;34:939–944.
Crossref
PubMed
Google Scholar
23.
Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol Epub 2011 Jul 11.
Google Scholar
24.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc B 1995;57:289–300.
Google Scholar
25.
Rowe CC, Ellis KA, Rimajovae M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275–1283.
Crossref
PubMed
Google Scholar
26.
Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative: The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer Dement 2010;6:221–229.
Crossref
PubMed
Google Scholar
27.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011;7:280–292.
Crossref
PubMed
Google Scholar
28.
Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119–128.
Crossref
PubMed
Google Scholar
29.
Amyvid (florbetapir F 18 injection) [product insert]. Indianapolis: Eli Lilly & Co; April 2012.
Google Scholar
30.
Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363–372.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 79 • Number 16 • October 16, 2012
Pages: 1636-1644
PubMed: 22786606

Copyright

Copyright © 2012 by AAN Enterprises, Inc.

Publication History

Received: December 22, 2011
Accepted: May 1, 2012
Published online: July 11, 2012
Published in print: October 16, 2012

Permissions

Request permissions for this article.

Disclosure

P.M. Doraiswamy has received research grants through Duke University from NIA, NIMH, NINDS, NHLBI, University of California (ADCS), Northern California Research Institute (ADNI), Avid/Lilly, Elan, Bristol-Myers, Ono, Sanofi, Novartis, Medivation, and Neuronetrix in the recent past. He has received advisory or speaking fees from Avid/Lilly, Medivation, BristolMyers, Accera, Sonexa, Schering, TauRx, Baxter, Neuroptix, Bayer, Neuronetrix, Otsuka, AstraZeneca, Lundbeck, and Edwards Hospital. He owns stock in Sonexa, Clarimedix, and Adverse Events Inc, whose products are not discussed in this manuscript. R.A. Sperling has served as a site investigator for Avid, BMS, Elan, Janssen, Pfizer, and Wyeth and as a consultant to Bayer, BMS, Elan, Eisai, Janssen, Pfizer, Roche, and Wyeth, and as an unpaid consultant to Avid. She has received speaking honoraria from Prizer, Janssen, Eli Lilly, and Bayer. R.E. Coleman was a site PI for the clinical study and served on an advisory board to Avid and Lilly. K.A. Johnson was a co-investigator in the trial and has consulted for GE Healthcare, Bayer-Schering, Pfizer, Elan/Janssen, and Seimens. He has received research support from Avid/Lilly, Bristol-Myers-Squib, Janssen (JanssenAI), and Pfizer. E.M. Reiman has served as a scientific advisor to Sygnis, AstraZeneca, Bayer, Eisai, Elan, Eli Lilly, GlaxoSmithKline, Intellect, Link Medicine, Novartis, Siemens, and Takeda. He has had research contracts with NIA the Arizona Dept. of Health Services, AstraZeneca, and Avid. M.D. Davis has received training support from NIDDK grant 2T32DK060455, is an employee at Theorem Clinical Research, and performed statistical analyses under a contract from Avid. M. Grundman has served as a consultant to Acumen, Adamas, ALSP, Avid, Biogen Idec, Elan, Helicon, Intellect Neurosciences, Janssen Alzheimer Immunotherapy, J&J, Lilly, Neurophage, and Teva and on advisory boards for Helicon, Nutricia North America, and Bristol Myers Squibb. He owns stock in Elan and formerly held Avid stock options. M.N. Sabbagh has served in a consulting or advisory capacity for Lilly, Amerisciences, Takeda, Eisai, Pfizer, and GSK and has received royalties from Wiley and Amerisciences. He has received contracts and grants from Celgene, Ceregene, Bayer, Baxter, BMS, Lilly, Pfizer, Wyeth, Janssen, Elan, Avid, Genentech, and Eisai. C.H. Sadowsky has served on speaker bureaus for Novartis, Forest, and Accera and as a consultant to Lilly. A.S. Fleisher has served as a consultant to Lilly and Avid and received grant funding from Avid. A. Carpenter is an employee of Avid, a division of Eli Lilly, and formerly held Avid stock or options. C.M. Clark, deceased, was an employee at Avid; disclosures are not included for this author. A.D. Joshi, M.A. Mintun, D.M. Skovronsky, and M.J. Pontecorvo are employees of Avid, a division of Eli Lilly, and formerly held Avid stock or options. Go to Neurology.org for full disclosures.

Authors

Affiliations & Disclosures

P. Murali Doraiswamy, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
1) Avid/Lilly, 2)Medivation, 3) BristolMyers, 4) Accera, 5) Sonexa, 6) Schering, 7) TauRx, 8) Baxter, 9)Neuroptix, 10) Bayer, 11) Neuronetrix
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1) Accera, 2) Lundbeck, 3) AstraZeneca, 4) Edwards Hospital, 5) University California, 6) National University of Singapore
Editorial Boards:
1.
Pharmacotherapy (editorial board member)
Patents:
1.
NONE
Publishing Royalties:
1.
The Alzheimer’s Action Plan, 2008, St Martins Press
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1) Rutgers University, 2) NIH
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Research grants to Duke university from 1) Avid, 2) Elan, 3) Lilly, 4) BristolMyers, 5)Ono, 6) Sanofi, 7) Novartis, 8) Medivation, 9) Neuronetrix
Research Support, Government Entities:
1.
1) NIA, 2) NIMH, 3) NINDS, 4)NHLBI
Research Support, Academic Entities:
1.
1) University of California - ADCS, 2) Northern California Research Institute - ADNI
Research Support, Foundations and Societies:
1.
Alzheimer Drug Discovery Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
1) Sonexa, 2) Clarimedix, 3)AdverseEvents Inc
Legal Proceedings:
1.
NONE
View all articles by this author
Reisa A. Sperling, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Pfizer - AD/PD symposium speaker honorarium
Editorial Boards:
1.
Alzheimer’s Disease and Associated Disorders 2007-2010
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
has served as a consultant for Roche, Janssen, Pfizer Inc, Bayer Schering Pharma, Eisai Inc., Satori, Kyowa Hakko Kirin, Bristol-Myers Squibb and Avid Radiopharmaceuticals, (unpaid);
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Janssen, clinical trial investigator 2008-2009,Bristol- Myers-Squibb, clinical trial investigator 2009-2010
Research Support, Government Entities:
1.
1) National Institute on Aging R01AG027435, principal investigator, 2006-2012; 2) National Institute on Aging P01AG036694, principal investigator, 2010-2015. 3) National Institute on Aging P50 AG005134, 2008-2013; Project leader.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzheimer’s Association, principal investigator, 2007-2009 Anonymous Foundation, principal investigator, 2009-2010 American Health Assistance Foundation, principal investigator, 2010.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
R. Edward Coleman, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Deceased.
Disclosure
Scientific Advisory Boards:
1.
Medical advisory board--Avid Radiopharmaceuticals, Inc; and Lilly(2011,2012); Bayer; Speakers’ Bureaus: Lilly;
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
Department of Radiology, Duke University Medical Center,Amyloid imaging study,<5%
Research Support, Commercial Entities:
1.
Clinical Trial, Avid Radiopharmaceuticals Inc. (2011,2012)
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Keith A. Johnson, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Pfizer Inc., travel and speaker honoraria
Editorial Boards:
1.
Journal of Neuroimaging, Associate Editor, 2005-2012
Patents:
1.
NONE
Publishing Royalties:
1.
The Whole Brain Atlas, Williams and Wilkins, 1999
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1) GEHC Ltd; 2) Avid/Lilly ; 3) Bayer-Schering; 4) Pfizer; 5) Elan/Janssen; 6) Bristol-Myers-Squib
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
1) Division of Nuclear Medicine and Molecular Imaging, Department of Imaging, Massachusetts General Hospital, Boston, MA., <5%, 2002-2011; 2) Memory Disorders Unit, Department of Neurology, Brigham and Women’s Hospital, Boston, MA., <5%, 1993-2011.
Research Support, Commercial Entities:
1.
1) Avid/Lilly; 2) Bristol-Myers-Squib; 3) Janssen (JanssenAI); 4) Pfizer
Research Support, Government Entities:
1.
1) NIH/NIA R01 AG037497, principal investigator, 2010- 2011; NIH/NIA: R01 AG027435S, co-princpal investigator, 2005- 2011; P50 AG00513421, co-investigator, 2002-2011; P01 AG036694 co-principal investigator, 2009-2011; R01 AG021910, co-investigator, 2008-2011; K23 AG033634, sponsor/mentor, 2009-2011; NIH/NINDS R01 NS062028, co- investigator, 2008-2011; NIH/NINDS R01 AG026484, co- investigator, 2010-2011; NIH/NIA R21 AG038994, co- investigator, 2011
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alzheimer Association ZEN-10-174210, principal investigator, 2010-2011; Alzheimer Association IIRG-08-90934, co- investigator, 2008-2011; American Health Assistance Foundation, co-investigator, 2010-2011
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Eric M. Reiman, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
Accera Bayer Elan Eli Lilly AstraZeneca GlaxoSmithKline Siemens Takeda Eisai
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Deputy Editor, Journal of Clinical Psychiatry
Patents:
1.
Patent held: “Methods for Tracking the Progression of Alzheimer’s Disease Identifying Treatment Using Transgenic Mice
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Kronos Life Sciences GlaxoSmithKline AstraZeneca Avid
Research Support, Government Entities:
1.
NIA (R01 AG031581, PI) NIA (P30 AG19610, PI) State of Arizona (Arizona Alzheimer’s Consortium, PI)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Banner Alzheimer’s Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mat D. Davis, MS
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Theorem Clinical Research, Statistician
Consultancies:
1.
Performed statistical consulting for Avid Radiopharmaceuticals
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), Grant Number 2T32DK060455, Statistician, 2010-2011
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michael Grundman, MD, MPH
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
Helicon, Nutricia North America, Bristol Myers Squibb
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Acumen, Adamas, ALSP, Avid, Biogen Idec, Elan, Helicon, Intellect, Janssen Alzheimer Immunotherapy, Johnson& Johnson, Lilly, Neurophage, Teva
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
Elan, Avid
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Marwan N. Sabbagh, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
Amerisciences. I am chair of the SAB. It is a nutracuetical company. I am chair of the DSMB for Allon Pharmaceuticals. Chair the DSMB for Allan Pharmaceuticals PSP RCT
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
CLincal Neurology News, and Journal of Alzheimer’s Disease, BMC Neurology
Patents:
1.
NONE
Publishing Royalties:
1.
From the published book
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Advisory boards for GSK, Pfizer, BMS, Eisai, Amerisciences, Avid, Lilly, Takeda
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Support from Elan, Wyeth, Medivation, Avid, Baxter, Lilly, GE, Eisai, Bayer, Pfizer, BMS
Research Support, Government Entities:
1.
The NIA from the ADCC P30 and NIH RO1
Research Support, Academic Entities:
1.
The Alzheimer’s disease cooperative study, ADNI
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
Amerisciences pays royalties on the commercial product Cognivite
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Carl H. Sadowsky, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
1)Commercial: advisory board for Lilly 2)Commercial: advisory board for Novartis 3)Commercial: advisory board for Accera
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1)Commercial: Lilly 2)Commercial: Avid 3)Commercial: Novartis 4)Commercial: Accera 5)Commercial: Forrest Speakers’ Bureaus: 1)Commercial: Lilly 2)Commercial: Avid 3)Commercial: Novartis 4)Commercial: Accera 5)Commercial: Forrest
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Adam S. Fleisher, MD, MAS
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NIH funded grant for the study of omega 3 fatty acids in AD, DSMB Chair. SAB Eli-Lilly, Semagacestat SAB Elan,Scilo-inositol
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Employed by The Banner Alzheimer’s Institute, Non-profit
Consultancies:
1.
Dr. Fleisher has served as a consultant for Elan, Pfizer, Janssen and Wyeth Pharmaceuticals.
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Investigator initiated grant - Avid radiopharma, a whole- owned subsidiary of Eli-Lilly
Research Support, Government Entities:
1.
CO-INVESTIGATOR: NIA R01 AG031581 2008-2013 CO-INVESTIGATOR: NIA RC2 AG036535 2009-2011 PI NIA 1 K23 AG024062 2004-2009 Consultant NIA 5 U01 AG10483 2007-2012
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Alan Carpenter, PhD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Avid Radiopharmaceuticals, Inc., Vice President, Regulatory Affairs
Consultancies:
1.
Avid Radiopharmaceuticals, Inc.
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Employment at Avid Radiopharmaceuticals, Inc.
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
Avid Radiopharmaceuticals, Inc.
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Christopher M. Clark, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Deceased.
View all articles by this author
Abhinay D. Joshi, MS
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Avid Radiopharmaceuticals Inc.
Consultancies:
1.
NONE
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mark A. Mintun, MD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Avid Radiopharmaceuticals, Inc., Chief Medical Officer
Consultancies:
1.
NONE
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
Stock options in 2010 from Avid Radiopharmaceuticals
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Daniel M. Skovronsky, MD, PhD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Eisai: honorarium for speaking at 50th Annual Japanese Society of Nuclear Medicine Meeting 2010. Eisai: reimbursement of travel to 50th Annual Japanese Society of Nuclear Medicine Meeting 2010.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Avid Radiopharmaceuticals, Inc. a wholly-owned subsidiary of Eli Lilly & Company - Chief Executive Officer
Consultancies:
1.
NONE
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
Avid Radiopharmaceuticals, Inc. - Stock and Stock Options 2010
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michael J. Pontecorvo, PhD
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Avid Radiopharmaceuticals, a wholely owned swubsidiary of Eli Lilly Inc., Vice President Clinical Development
Consultancies:
1.
NONE
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
Avid Radiopharmaceuticals: Stock Options 2010
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
For the AV45-A11 Study Group
From the Duke University Medical Center (P.M.D., R.E.C.), Durham, NC; Massachusetts General Hospital (R.A.S., K.A.J.), Harvard Medical School, Boston; Banner Alzheimer's Institute (E.M.R., A.S.F.), Phoenix, AZ; University of Pennsylvania (M.D.D.), Philadelphia; Theorem Clinical Research (M.D.D.), King of Prussia, PA; Global R&D Partners (M.G.), San Diego, CA; University of California (M.G., A.S.F.), San Diego; Banner-Sun Health Research Institute (M.N.S.), Sun City, AZ; Nova SE University (C.H.S.), Ft. Lauderdale, FL; and Avid Radiopharmaceuticals (A.C., C.M.C., A.D.J., M.A.M., D.M.S., M.J.P.), Philadelphia, PA.
View all articles by this author

Notes

Coinvestigators are listed on the Neurology® Web site at www.neurology.org.
Correspondence & reprint requests to Dr. Doraiswamy: [email protected]; Dr. Pontecorvo: [email protected]

Author Contributions

P.M.D. served as the primary author of the manuscript, advised on study design, assisted with data collection, drafted the initial version of the manuscript, and was involved in data interpretation and critical revisions. R.A.S. contributed to data collection and manuscript revisions. R.E.C. contributed to subject recruitment and participated in manuscript writing. K.A.J. collected data and revised the manuscript. E.M.R. contributed to the study design, interpretation of the findings, and reviewing the manuscript. M.D.D. performed the statistical analyses. M.G. contributed to the data analysis, interpretation, and manuscript revisions. M.N.S. contributed to data collection, manuscript review, and study design. C.H.S. contributed to data collection and reviewing the manuscript. A.F. contributed to data collection and editing the manuscript. A.C. contributed to study design, data review, and interpretation. C.M.C. contributed to study design and data interpretation. A.D.J. contributed to study design, reviewing the literature, drafting figures, and drafting the manuscript. M.A.M. contributed to administrative support, funding, data analysis, and manuscript review. D.M.S. contributed to study design, data review, and manuscript writing. M.J.P. contributed to study design, conduct, data analysis and interpretation, and review of the manuscript.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Keith L. Sanders,
    • Astrid M. Manuel,
    • Andi Liu,
    • Boyan Leng,
    • Xiangning Chen,
    • Zhongming Zhao,
    Unveiling Gene Interactions in Alzheimer’s Disease by Integrating Genetic and Epigenetic Data with a Network-Based Approach, Epigenomes, 8, 2, (14), (2024).https://doi.org/10.3390/epigenomes8020014
    Crossref
    • Brenda L. Plassman,
    • Cassie B. Ford,
    • Valerie A. Smith,
    • Nicole DePasquale,
    • James R. Burke,
    • Laura Korthauer,
    • Brian R. Ott,
    • Emmanuelle Belanger,
    • Megan E. Shepherd-Banigan,
    • Elyse Couch,
    • Eric Jutkowitz,
    • Emily C. O’Brien,
    • Corinna Sorenson,
    • Terrie T. Wetle,
    • Courtney H. Van Houtven,
    Elevated Amyloid-β PET Scan and Cognitive and Functional Decline in Mild Cognitive Impairment and Dementia of Uncertain Etiology, Journal of Alzheimer's Disease, 97, 3, (1161-1171), (2024).https://doi.org/10.3233/JAD-230950
    Crossref
    • Jason Langley,
    • Ilana J. Bennett,
    • Xiaoping P. Hu,
    Examining iron‐related off‐target binding effects of 18 F‐AV1451 PET in the cortex of Aβ+ individuals , European Journal of Neuroscience, 60, 1, (3614-3628), (2024).https://doi.org/10.1111/ejn.16362
    Crossref
    • Aaron Bangad,
    • Mehdi Abbasi,
    • Sam Payabvash,
    • Adam de Havenon,
    Imaging of Amyloid-beta-related Arteritis, Neuroimaging Clinics of North America, 34, 1, (167-173), (2024).https://doi.org/10.1016/j.nic.2023.09.001
    Crossref
    • Eric G. Klein,
    • Krista Schroeder,
    • Alette M. Wessels,
    • Adam Phipps,
    • Maureen Japha,
    • Traci Schilling,
    • Jennifer A. Zimmer,
    How donanemab data address the coverage with evidence development questions, Alzheimer's & Dementia, 20, 4, (3127-3140), (2024).https://doi.org/10.1002/alz.13700
    Crossref
    • Mengjie Wang,
    • Zhengwei Zhang,
    • Ying Wang,
    • Lin Huang,
    • Qi Huang,
    • Shuhua Ren,
    • Luojun Qian,
    • Ruiqing Ni,
    • Qihao Guo,
    • Yihui Guan,
    • Fang Xie,
    Effect of APOE ɛ4 Status on Brain Amyloid‐β and Cognitive Function in Amnestic and Nonamnestic Mild Cognitive Impairment: A [18F] Florbetapir PET‐CT Study , Advanced Therapeutics, 7, 8, (2024).https://doi.org/10.1002/adtp.202400008
    Crossref
    • Petra Hnilicova,
    • Ema Kantorova,
    • Stanislav Sutovsky,
    • Milan Grofik,
    • Kamil Zelenak,
    • Egon Kurca,
    • Norbert Zilka,
    • Petra Parvanovova,
    • Martin Kolisek,
    Imaging Methods Applicable in the Diagnostics of Alzheimer’s Disease, Considering the Involvement of Insulin Resistance, International Journal of Molecular Sciences, 24, 4, (3325), (2023).https://doi.org/10.3390/ijms24043325
    Crossref
    • Stephanie S. Buss,
    • Peter J. Fried,
    • Joanna Macone,
    • Victor Zeng,
    • Emma Zingg,
    • Emiliano Santarnecchi,
    • Alvaro Pascual-Leone,
    • David Bartrés-Faz,
    Greater cognitive reserve is related to lower cortical excitability in healthy cognitive aging, but not in early clinical Alzheimer’s disease, Frontiers in Human Neuroscience, 17, (2023).https://doi.org/10.3389/fnhum.2023.1193407
    Crossref
    • Imas Kania Rahman,
    • Noneng Siti Rosidah,
    • Abas Mansur Tamam,
    Development of a Scale for Measuring the Competencies of Islamic Counselors, Islamic Guidance and Counseling Journal, 6, 1, (28-44), (2023).https://doi.org/10.25217/igcj.v6i1.3133
    Crossref
    • Pedram Ahmadnezhad,
    • Jeffrey M. Burns,
    • Abiodun E. Akinwuntan,
    • Maud Ranchet,
    • Alexandra Kondyli,
    • Jonathan D. Mahnken,
    • Hannes Devos,
    Driving Automation for Older Adults with Preclinical Alzheimer’s Disease, Gerontology, 69, 11, (1307-1314), (2023).https://doi.org/10.1159/000531263
    Crossref
  11. See more

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share

View full text|Download PDF